Building A Resilient Supply Chain For Your Next-Generation Peptide Therapeutic

By Brian Graves, Global Business Manager, Fine Chemical Manufacturing Services; James Springer, R&D Director; and Randall Andrews, Plant Manager, W. R. Grace & Co.

Peptide therapeutics are an innovative treatment option for cancer, obesity, diabetes, and more, thanks to their wide array of benefits, including high target specificity, low toxicity, and favorable safety profiles. This is reflected in the booming success of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, which are used to treat type 2 diabetes and obesity, and are currently being studied for a range of other applications.

As the peptide therapeutic market is slated to grow at an exponential rate in the coming years, drug sponsors are determining how best to navigate growing demand. Primarily, they must determine how to mitigate drug shortages and ensure continuous patient supply by establishing reliable partnerships with vendors. One critical vendor is the peptide building block supplier, who will help your team procure a reliable supply of high-quality starting materials. Download the full article to learn more about identifying the peptide building block supplier best suited for your project.